J Am Coll Cardiol June 2019 PMID 30898607

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, John Gregson, Stuart J Pocock, Christie M Ballantyne

Download social card

Mentions

Peak: 1 in Jun 2019

across 5 sources since Jun 2019

Extended reach

6,145

potential audience

Total likes

217

Video views

3,603

Mentions per month

Jun 2019 – Nov 2025

Where it's discussed

News47 articles
X / Twitter3 posts
Blogs3 articles
YouTube2 videos
Reddit2 posts

AI synopsis

What people are saying

Discussions reflect strong agreement, with posts stating omega-3's benefits in reducing inflammation and clotting, and noting that some countries now incorporate these findings into treatment recommendations. The tone combines scientific explanation with policy implications, showing both interest and engagement, though the overall perceived impact is moderate as the findings are already influencing practice.

AgreementModerate agreement

Most discussions endorse the positive findings of the REDUCE-IT study, emphasizing omega-3's proven benefits.

InterestHigh interest

The posts show high enthusiasm, with many referencing authoritative sources and mechanisms, indicating strong engagement.

EngagementHigh engagement

Participants actively discuss mechanisms, policy implications, and clinical relevance, demonstrating deep involvement.

ImpactModerate impact

The discussion highlights that the study's results are influencing global treatment guidelines, signifying moderate to high perceived impact.

Abstract in brief

Icosapent ethyl significantly lowered the risk of both first and subsequent ischemic events (like cardiovascular death) in statin-treated patients with high triglycerides.
The REDUCE-IT trial involved 8,179 patients with specific cholesterol and triglyceride levels, comparing the effects of icosapent ethyl to a placebo over about 4.9 years.
Results showed a substantial reduction in total primary endpoint events for those taking icosapent ethyl, with rates of 61 vs. 89 per 1,000 patient-years compared to placebo.

Read the full abstract

All mentions

Pemafibrate's Impact on Cardiovascular Risk in Diabetes Patients

This video discusses pemafibrate, a drug that lowers high triglyceride levels and improves lipids. A trial with nearly 10,500 patients showed that while it significantly reduced triglycerides, it did not lead to fewer…

Pyroliquid Science · Sep 1, 2024 1,985 views

Omega 3 Supplementation for Brain and Cardiovascular Health

This video explores the benefits of omega-3 fatty acids, their role in preventing cognitive decline and diseases like Alzheimer's, and the importance of maintaining proper omega-6 to omega-3 ratios for overall health…

What's Up Doctor? Dr Michael Cohen · Feb 14, 2023 1,619 views

Solon

@SolonsAccounts · X

@4corners https://t.co/fogkdQuYue This large scale study is now being used by some countries in recommendations Omega 3 definitively has a role in reducing inflammation, improving blood vessel, reducing platelet aggregation, reducing clotting Mechanisms are known too

Nov 6, 2025 · 14 followers View post →

Macrophysiological System

@InVitroFuture · X

Oct 30, 2025 · 1 like · 1,568 followers View post →

Dataemia

@Dataemia · X

Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT - https://t.co/qUIWDHfoUL https://t.co/XMjmuIN9VD

Jun 5, 2019 · 1 like · 961 followers View post →